Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 300

Results For "IND"

6614 News Found

Abbott receives FDA approval for TriClip
Drug Approval | April 04, 2024

Abbott receives FDA approval for TriClip

TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery


Max CMD Abhay Soi is new president of NATHEALTH
People | April 04, 2024

Max CMD Abhay Soi is new president of NATHEALTH

New leadership team announced at NATHEALTH Annual General Meeting 2024


EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes
Drug Approval | April 03, 2024

EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia


Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO  International Non-proprietary Names
News | April 02, 2024

Zydus receives approval for the name 'Usnoflast' as recommended name for ZYIL1 from WHO International Non-proprietary Names

Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus


Vivity reaches 1 million milestone
Healthcare | April 02, 2024

Vivity reaches 1 million milestone

Vivity is the first and only wavefront-shaping IOL with Alcon’s proprietary X-WAVE Technology


Viatris launches RYZUMVl 0.75% in US
News | April 02, 2024

Viatris launches RYZUMVl 0.75% in US

The average time of dilation lasts three to eight hours


MTD acquires Ypsomed's pen needle and BGM businesses
Medical Device | April 01, 2024

MTD acquires Ypsomed's pen needle and BGM businesses

This acquisition enables MTD to open new, strategic markets


Krazati monotherapy shows significant survival benefit in KRAS G12C-mutated NSCLC Phase III Krystal -12 data
Drug Approval | April 01, 2024

Krazati monotherapy shows significant survival benefit in KRAS G12C-mutated NSCLC Phase III Krystal -12 data

The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024